“There is an urgent need for – and the Alzheimer’s Association enthusiastically supports – a simple, inexpensive and scalable way to detect Alzheimer’s disease early and accurately. Advances in Alzheimer’s imaging and fluid biomarkers have enabled doctors and researchers to more accurately diagnose Alzheimer’s disease, select research participants and measure response to investigational therapies.
Blood-based tests for Alzheimer’s disease would be particularly welcomed by clinicians, researchers and the public. Once developed, validated and approved, a blood test for early and accurate detection of Alzheimer’s disease would allow those at risk to receive treatment in the early stages of the disease and better plan for the future — and it could speed drug development by identifying the right people for clinical trials.
The Alzheimer’s Association has consistently been a leader in supporting the development of blood-based biomarkers for more than a decade: from early funding of the basic science, to incorporation of initial testing technologies into the IDEAS Study, to our participation as a partner in the Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease Project.”
Maria C. Carrillo, Ph.D.
Chief Science Officer
Alzheimer’s Drug Discovery Foundation
“The strength and collective expertise of FNIH’s biomarker consortium is a great asset in our ability to evaluate the best amyloid blood tests for early detection of Alzheimer’s, which will help enroll the right patients into the right trials and monitor their progress in an efficient and cost-effective way,” said Howard Fillit, M.D., Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). “This is why the ADDF’s Diagnostics Accelerator was excited to provide funding for this important work.”
“Driven by our commitment to patients and our passion for neuroscience, Biogen is focused on furthering Alzheimer’s disease research and treatment. As part of this commitment, Biogen is proud to support the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ project. The Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease project aims to identify the optimal blood tests to aid in the detection of Alzheimer’s disease. We believe the ability to accurately predict the presence of beta amyloid in the brain through a blood test has the potential to transform the diagnosis and treatment of Alzheimer’s disease patients.”
Samantha Budd Haeberlein, PhD
Head of Neurodegeneration Development Unit
“At Janssen, we recognize the importance of leveraging cutting-edge science and technology to gain deeper insights and better detect central nervous system (CNS) disorders like Alzheimer’s disease (AD). We are honored to be a part of the Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease Project – an initiative that brings together leading industry and non-profit partners that share a common goal of ensuring a future where we can not only predict AD, but also improve outcomes for those living with – or caring for – the condition.”
Bill Martin, Ph.D.
Global Therapeutic Area Head, Neuroscience
Janssen Research & Development, LLC
“We at Takeda are passionate about advancing research to develop transformative therapies for patients suffering from untreatable diseases. By supporting and being a leading contributor to the Plasma ABeta project initiated by the FNIH, we have the opportunity to bring transformative medical developments to patients affected by dementia, and their caretakers who are so greatly in need of effective therapies. This project may help spur future innovations capable of defining dementias by molecular pathologies using simple blood based biomarker tests.”
Stephen Zicha, Ph.D.
Neuroscience Translational Medicine
Takeda Pharmaceutical Company Limited